GlassScriptPhysician profile
Nathan H Schwartz
NPI 1700981057
$944.18
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $32.92 · 2021: $35.88 · 2022: $138 · 2023: $175 · 2024: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $386.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $279.87 | 2022-2023 | Puraply Antimicrobial, Puraply |
| Treace Medical Concepts, INC. | $145.15 | 2024 | |
| In2bones USA, LLC | $122.41 | 2019 | |
| Hydrocision, INC. | $94.61 | 2019 | |
| Smith+Nephew, INC. | $94.46 | 2019-2021 | |
| Horizon Therapeutics Plc | $60.03 | 2019-2021 | |
| Averitas Pharma INC. | $27.62 | 2024 | Qutenza |
| Wright Medical Technology, INC. | $26.58 | 2019 | |
| Medtronic, INC. | $22.88 | 2024 | Venaseal |
| Stryker Corporation | $19.90 | 2023 | Fixos |
| Depuy Synthes Sales INC. | $15.60 | 2024 | |
| Baudax Bio INC. | $13.68 | 2022 | |
| Merck Sharp & Dohme LLC | $11.24 | 2019 | |
| Orthofix Medical, INC. | $10.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.